Clinical trials: Late Onset Alzheimer Disease
Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis
Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders
The goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neurological and psychiatric disorders such as Alzheimer's disease (AD)…
- Conditions
- Alzheimer Dementia (AD), ALS - Amyotrophic Lateral Sclerosis, Parkinson s Disease, REM Sleep Behavior Disorder (iRBD)
- Trial name
- NCT07509125
- Testing
- UHR PET/CT scan of the brain with ¹⁸F-FDG, UHR PET/CT scan of the brain with ¹⁸F-PE2I, UHR PET/CT scan of the brain with ¹⁸F-SynVesT-1
- Where
- Belgium
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Alzheimer Disease, Alzheimer Disease, Late Onset
Transcranial Electromagnetic Treatment Against Alzheimer's Disease
This is an extension of EM 1000-1 wherein subjects who participated in the original study have been given the opportunity to participate in a 4-month extension of TEMT.
- Trial name
- NCT03927040
- Testing
- MemorEM 1000
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- NeuroEM Therapeutics, Inc.
Alzheimer Disease, Late Onset, Alzheimer Disease
Network-based rTMS in Alzheimer's Disease
Severe alterations of brain networks connectivity have been described in Alzheimer's disease (AD). Repetitive Transcranial Magnetic Stimulation (rTMS) has gained evidence as an effective tool to modulate brain networks…
- Conditions
- Alzheimer Disease, Late Onset, Alzheimer Disease, Cognitive Deterioration
- Trial name
- NCT04263194
- Testing
- rTMS
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Alzheimer Disease, Alzheimer Disease 1
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Alzheimer's disease.
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT04100889
- Testing
- No Intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Alzheimer Disease 2 Due to Apoe4 Isoform
Acute Exercise on Neurocognitive Function Among Adults With/Without Generic Risk of AD
This study explores the acute exercise effect on neurocognitive function and also its potential moderators in an exercise setting and Apolipoprotein E (APOE) genetic risk.
- Trial name
- NCT05591313
- Testing
- LI-40, MI-30, HI-16
- Where
- Taiwan
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- National Taiwan Normal University
Late Onset Alzheimer Disease
Expanded Access With Trappsol(R) Cyclo (TM) for an Individual Patient With Late Onset Alzheimer's Disease
To afford urgent access to a potential-disease modifying treatment, Dr. Diana Kerwin, in partnership with CTD Holdings, the manufacturer of Trappsol (R) Cyclo(TM), will administer the product to a patient with Alzheimer's Disease…
- Trial name
- NCT03624842
- Testing
- Trappsol (R) Cyclo (TM)
- Sponsor
- Cyclo Therapeutics, Inc.
Alzheimer Disease, Dementia
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease, Dementia, Neurodegenerative Disorders, Cognitive Decline
- Trial name
- ADKIT (NCT07294586)
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease, Early Onset, Alzheimer Disease
Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)
The Etude Study is a multi-center, four-arm prospective dose-adjusting study designed to assess the tolerability, safety and efficacy of non-invasive sensory stimulation for patients with cognitive impairment.
- Conditions
- Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Dementia, Mild Cognitive Impairment
- Trial name
- NCT03661034
- Testing
- GammaSense Stimulation System (non-invasive, non-significant risk)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cognito Therapeutics, Inc.
Alzheimer Disease, Early Onset, Alzheimer Disease
Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks
This study attempts to identify two types of AD by using clinical and cognitive tasks and brain imaging. The subtypes of AD are separated into a "typical" group (memory loss) and a "variant" group (language, visuospatial, and…
- Conditions
- Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Disease, Late Onset, Dementia, Alzheimer Type
- Trial name
- EOAD-Subtype (NCT03153371)
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Alzheimer Dementia, Late Onset Alzheimer Disease
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
- Conditions
- Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases
- Trial name
- REGEN-BRAIN© (NCT04838301)
- Testing
- Allopregnanolone
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Arizona
Late Onset Alzheimer
Good Rate of Clinical Response to Cholinesterase Inhibitors in Alzheimer's Disease After Three Months of Treatment
Life expectancy in Brazil has increased markedly over the last 30 years. Hence, age-related disorders, such as Alzheimer's disease (AD), warrant special attention due to their high prevalence in the elderly.
- Trial name
- NINDS-AIREN (NCT02007291)
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Late Onset Alzheimer Disease
Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172
The overall goal of this project is to establish and validate biomarkers associated with the risk and progression of late onset Alzheimer's disease, mild cognitive impairment and cognitive decline.
- Trial name
- NCT01222351
- Testing
- BAY 94-9172 (Florbetaben)
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- New York State Psychiatric Institute
Alzheimer Disease 2 Due to Apoe4 Isoform, Healthy Aging
Dementia Risk and Dynamic Response to Exercise
Research suggests that physical exercise supports brain health and cognition as we age. The goal of this project is to examine the specific changes in brain blood flow and biological factors in the blood immediately after…
- Trial name
- DYNAMIC (NCT04009629)
- Testing
- Moderate Intensity Aerobic Exercise
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Alzheimer Disease, Late Onset, Mild Cognitive Impairment
Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease
Dementia caused by Alzheimer's disease affects approximately 5.6 million adults over age 65, with costs expected to rise from $307 billion to $1.5 trillion over the next 30 years.
- Conditions
- Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Sleep, Cognitive Change
- Trial name
- ALPS (NCT05138848)
- Testing
- Time in Bed Restriction, Sleep Schedule
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Dementia, Alzheimer Disease, Late Onset
Reducing Risk of Dementia Through Deprescribing
A cluster-randomized controlled trial (RCT) called "Reducing Risk of Dementia through Deprescribing" (R2D2) to evaluate the impact of a deprescribing intervention on important cognitive and safety outcomes.
- Trial name
- R2D2 (NCT04270474)
- Testing
- Deprescribing of target anticholinergics, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 344 people
- Sponsor
- Indiana University
ALS, Amyotrophic Lateral Sclerosis
NYSCF Scientific Discovery Biobank
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells…
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset
- Trial name
- NCT06203106
- Testing
- Biological Sample Collection
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- New York Stem Cell Foundation Research Institute
Alzheimer Disease, Alzheimer Disease 1
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)
This is a randomized, double-blind, sham-controlled pivotal study of sensory stimulation in subjects with mild to moderate AD. Up to approximately 670 subjects will be treated with either Active or Sham investigational device…
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- HOPE (NCT05637801)
- Testing
- Spectris™ AD - Active
- Where
- 68 sites in United States
- Volunteers
- 673 people
- Sponsor
- Cognito Therapeutics, Inc.
Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset
China Cognition and Aging Study
The aim of this study is to establish and perfect the China Cognition and Aging Study (China COAST) cohort, to clarify the epidemiology, influencing factors, genetic characteristics, pathogenesis, disease characteristics and…
- Conditions
- Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset, Familial Alzheimer Disease (FAD), Vascular Dementia (VaD)
- Trial name
- COAST (NCT03653156)
- Where
- 65 sites in China
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Capital Medical University
Alzheimer Disease, Late Onset
Synaptic Injury and Functional Connectivity in Alzheimer's Disease
The purpose of this study is to examine cross-sectional associations between CSF markers of synaptic injury (Ng and SNAP-25) and functional connectivity in default and semantic memory networks using 3T- fMRI in individuals with…
- Trial name
- NCT03300726
- Testing
- CSF analysis, Functional MRI
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Alzheimer's Disease, Late Onset
Effects of Aerobic Exercise for Treating Alzheimer's Disease
This randomized controlled trial (RCT) will investigate the effects of a 6-month, individualized, moderate-intensity cycling intervention on cognition and hippocampal volume in AD with three aims: Determine the immediate effect…
- Trial name
- FIT-AD (NCT01954550)
- Testing
- Cycling exercise, Range of motion/stretching exercise
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- University of Minnesota